Developer docs
API playgroundTry for free, no card

Search company profiles

Barcode

Full company profile

uuid0003ida

Namestring
Barcode
Legal namestring
Barcode Nanotech
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Barcode Nanotech is a privately held Israeli biotechnology company founded in 2017 and headquartered in Nazareth, Israel. The company develops lipid nanoparticle (LNP) delivery vehicles designed to transport RNA and DNA-based therapeutics and vaccines to specific tissues and cells beyond the liver, addressing a central bottleneck in the RNA therapeutics field where conventional LNPs are predominantly liver-tropic. Its core platform combines an in vivo mass screening capability using molecular barcoding to simultaneously evaluate hundreds of nanoparticle formulations in a single experiment with AI analysis tools that select the optimal delivery vehicle for each target tissue, supported by a proprietary library of novel lipids engineered for selective targeting. The platform has demonstrated capability across liver, lung, tumor, brain, kidney, spleen, and vaccine applications.

The company sells to pharmaceutical and biotechnology developers of RNA and DNA-based drugs and vaccines through a B2B partnership-driven go-to-market. Revenue mechanics are expected to flow from licensing fees, milestone payments, royalties, and collaborative R&D services negotiated under individual co-development agreements; pricing is not publicly disclosed. A named strategic co-development partnership is in place with Galmed Pharmaceuticals for a brain-penetrating LNP formulation of Aramchol targeting CNS diseases, with clinical trials targeted for 2026. Barcode operates with a lean 1–10 person team led by CEO and co-founder Ronen Eavri (former J&J, D-Pharm) and CTO and co-founder Annie Sabbah (former MPT Diagnostics, Rambam/Technion), supported by an R&D team leader, a chemistry lead, a molecular biology specialist, and an AI/bioinformatics specialist, along with scientific and medical advisory boards. The company is privately held, was previously funded by a $4 million OurCrowd round in March 2019, and is currently raising capital to scale partnerships and pipeline development.

Short descriptiontext

Barcode Nanotech is an Israeli biotech developing lipid nanoparticle delivery vehicles for RNA and DNA therapeutics. Its AI-coupled in vivo mass screening platform enables selective tissue targeting beyond the liver for pharmaceutical partners developing vaccines and treatments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNazareth, Israel
HQ citystring
Nazareth
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
lipid nanoparticle delivery, RNA therapeutics platform, drug delivery technology, nanoparticle formulation services, in vivo screening platform
Industry3 codes
PRIMARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Drug Delivery Technology
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Partnership and Licensing Deals
TypeLicensing Royalties
Description

Revenue generation through strategic partnerships with pharmaceutical companies for co-development of RNA therapeutics. The company develops proprietary delivery vehicles and partners with drug developers, likely through licensing fees, milestone payments, and potential royalty arrangements.

barcode-nano.com
2Research and Development Collaborations
TypeProfessional Services
Description

Collaborative R&D arrangements with pharma companies to develop custom nanoparticle delivery solutions for specific therapeutic programs.

barcode-nano.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Barcode Nanotech develops and licenses proprietary lipid nanoparticle (LNP) delivery vehicles and an AI-powered in vivo screening platform that enables pharmaceutical partners to deliver RNA and DNA-based therapeutics and vaccines to precise tissue and cellular targets beyond the liver. The company partners with pharma and vaccine developers on co-development, licensing, and R&D collaboration arrangements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Hundreds of delivery vehicles developed and tested for different therapeutic drugs
+2 more records
Product overview1 text field

Barcode Nanotech offers a unified platform for RNA/DNA therapeutic delivery, comprising three interconnected components: a proprietary lipid library for RNA/DNA encapsulation and delivery, an in vivo mass screening platform using molecular barcoding technology with AI analysis to identify optimal delivery vehicles, and lipid-based nanoparticle formulations. The platform enables development of selective delivery vehicles targeting tissues including liver, lung, tumor, vaccines, kidney, spleen, and brain.

Product and service3 records
1Proprietary Lipid Library
CategoryDrug Delivery Technology
Description

A proprietary library of novel lipids developed for RNA and DNA encapsulation and LNP-based delivery, designed through an in vivo screening platform to enable selective and efficient targeting of designated cells and tissues. Licensed to pharmaceutical partners for use in RNA and DNA-based therapeutics and vaccines.

2In Vivo Mass Screening Platform
CategoryDrug Delivery Technology
Description

A proprietary screening platform that uses molecular barcoding to simultaneously evaluate hundreds of lipid nanoparticle formulations in vivo with rapid feedback loops. Identifies and quantifies nanoparticle biodistribution at single-cell resolution and uses AI analysis to select optimal delivery vehicles for each target tissue or cell.

3Lipid-Based Nanoparticle Delivery Vehicles
CategoryDrug Delivery Technology
Description

Proprietary lipid-based nanoparticle formulations for delivery of RNA and DNA-based therapies to targets beyond the liver, optimized for selective indications including hard-to-treat cancers, metabolic diseases, and other therapeutic areas. Made available to pharmaceutical partners through co-development and licensing arrangements.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-09
Description

Galmed Pharmaceuticals partnered with Barcode Nanotech to develop a brain-penetrating formulation of Aramchol (SCD1 inhibitor) using lipid nanoparticles for treating CNS diseases such as Parkinson's disease. The formulation is based on Barcode's proprietary nanoparticle platform and plans to advance to clinical trials in 2026.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeOthers
Description

Cytiva acquired Precision NanoSystems, a provider of LNP formulation instruments and lipid libraries used by RNA therapy developers. It is an enabling technology supplier and adjacent competitor whose lipid library offerings overlap with portions of Barcode's proprietary lipid asset.

TypeEmerging player
Description

Sirnaomics is a clinical-stage RNA therapeutics company with its own siRNA and mRNA delivery platforms targeting tumors and fibrotic diseases. It is an emerging peer with partial overlap in delivery-driven RNA approaches for oncology and metabolic indications that Barcode also pursues.

TypeEmerging player
Description

CureVac is an mRNA technology company developing its own lipid delivery formulations for vaccines and therapeutics. It is an emerging player that competes with Barcode for partnerships where RNA delivery know-how is a key differentiator, and overlaps on the RNA vaccine delivery use case.

TypeBroad incumbent
Description

Alnylam is the established leader in RNA-targeted therapeutics (siRNA) with proprietary conjugate-based delivery (GalNAc) and growing LNP programs. It is a broad incumbent addressing many of the same therapeutic indications Barcode targets, and represents the type of large pharma partner Barcode's LNP platform is designed to serve.

5Eveon
TypeEmerging player
Description

Eveon develops microfluidic formulation and manufacturing platforms for lipid nanoparticles and complex injectable drugs. It is an emerging peer addressing the same LNP formulation and process development market that Barcode's platform touches through its proprietary lipid library and screening workflow.

TypeBroad incumbent
Description

BioNTech is a vertically integrated mRNA therapeutics company with internal LNP capabilities and the resources to develop next-generation delivery formulations. It is a broad incumbent that competes with Barcode both as a potential partner and a potential internal-development alternative for pharma partners evaluating LNP technologies.

TypeBroad incumbent
Description

Moderna operates one of the largest internal LNP and mRNA delivery programs globally, with extensive in-house lipid libraries and biodistribution know-how. It is a broad incumbent whose size and resources set the benchmark Barcode's differentiated screening platform must beat on cost, speed, or tissue selectivity.

TypeDirect peer
Description

Acuitas is the leading independent LNP delivery technology company, supplying ionizable lipids used in Comirnaty and other approved RNA therapeutics. It is the most directly comparable peer to Barcode, competing head-to-head for pharma LNP licensing deals targeting tissues beyond the liver.

TypeDirect peer
Description

Genevant develops lipid nanoparticle and other delivery technologies for RNA therapeutics, licensing its platform to multiple pharma partners. It competes directly with Barcode for enterprise partnerships and embodies the same platform-licensing business model.

TypeDirect peer
Description

Arcturus combines proprietary LNP delivery technology with its own RNA therapeutic pipeline, including rare disease and infectious disease programs. It is a direct peer in the targeted RNA delivery space and operates a hybrid licensing-plus-product model similar to where Barcode could evolve.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability2 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Barcode

Drug Delivery Technologybarcode-nano.com

Barcode Nanotech is an Israeli biotech developing lipid nanoparticle delivery vehicles for RNA and DNA therapeutics. Its AI-coupled in vivo mass screening platform enables selective tissue targeting beyond the liver for pharmaceutical partners developing vaccines and treatments.

What Barcode does

Barcode Nanotech is a privately held Israeli biotechnology company founded in 2017 and headquartered in Nazareth, Israel. The company develops lipid nanoparticle (LNP) delivery vehicles designed to transport RNA and DNA-based therapeutics and vaccines to specific tissues and cells beyond the liver, addressing a central bottleneck in the RNA therapeutics field where conventional LNPs are predominantly liver-tropic. Its core platform combines an in vivo mass screening capability using molecular barcoding to simultaneously evaluate hundreds of nanoparticle formulations in a single experiment with AI analysis tools that select the optimal delivery vehicle for each target tissue, supported by a proprietary library of novel lipids engineered for selective targeting. The platform has demonstrated capability across liver, lung, tumor, brain, kidney, spleen, and vaccine applications.

The company sells to pharmaceutical and biotechnology developers of RNA and DNA-based drugs and vaccines through a B2B partnership-driven go-to-market. Revenue mechanics are expected to flow from licensing fees, milestone payments, royalties, and collaborative R&D services negotiated under individual co-development agreements; pricing is not publicly disclosed. A named strategic co-development partnership is in place with Galmed Pharmaceuticals for a brain-penetrating LNP formulation of Aramchol targeting CNS diseases, with clinical trials targeted for 2026. Barcode operates with a lean 1–10 person team led by CEO and co-founder Ronen Eavri (former J&J, D-Pharm) and CTO and co-founder Annie Sabbah (former MPT Diagnostics, Rambam/Technion), supported by an R&D team leader, a chemistry lead, a molecular biology specialist, and an AI/bioinformatics specialist, along with scientific and medical advisory boards. The company is privately held, was previously funded by a $4 million OurCrowd round in March 2019, and is currently raising capital to scale partnerships and pipeline development.

Barcode firmographics

Firmographics
Name
Barcode
Legal name
Barcode Nanotech
Website
https://barcode-nano.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Short description
Barcode Nanotech is an Israeli biotech developing lipid nanoparticle delivery vehicles for RNA and DNA therapeutics. Its AI-coupled in vivo mass screening platform enables selective tissue targeting beyond the liver for pharmaceutical partners developing vaccines and treatments.
Ownership category
akta.pro rank

Barcode industry classification

Industry
Product category
Drug Delivery Technology
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAADAD
RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAACAC
Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Gene Therapy (AAV/lentiviral/other vectors)
SECONDARYHLAAAEAD
Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Lipid nanoparticle delivery
  • RNA therapeutics platform
  • Drug delivery technology
  • Nanoparticle formulation services
  • In vivo screening platform

Where Barcode is headquartered

Location

Headquarters

HQ city
Nazareth
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Barcode business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Partnership and Licensing Deals: Revenue generation through strategic partnerships with pharmaceutical companies for co-development of RNA therapeutics. The company develops proprietary delivery vehicles and partners with drug developers, likely through licensing fees, milestone payments, and potential royalty arrangements.
  2. Research and Development Collaborations: Collaborative R&D arrangements with pharma companies to develop custom nanoparticle delivery solutions for specific therapeutic programs.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels3 records

Barcode product offering

Product offering

Core offering

Barcode Nanotech develops and licenses proprietary lipid nanoparticle (LNP) delivery vehicles and an AI-powered in vivo screening platform that enables pharmaceutical partners to deliver RNA and DNA-based therapeutics and vaccines to precise tissue and cellular targets beyond the liver. The company partners with pharma and vaccine developers on co-development, licensing, and R&D collaboration arrangements.

Product overview

Barcode Nanotech offers a unified platform for RNA/DNA therapeutic delivery, comprising three interconnected components: a proprietary lipid library for RNA/DNA encapsulation and delivery, an in vivo mass screening platform using molecular barcoding technology with AI analysis to identify optimal delivery vehicles, and lipid-based nanoparticle formulations. The platform enables development of selective delivery vehicles targeting tissues including liver, lung, tumor, vaccines, kidney, spleen, and brain.

Differentiator

Problem solved

Functional benefit

Products and services

  • Proprietary Lipid Library A proprietary library of novel lipids developed for RNA and DNA encapsulation and LNP-based delivery, designed through an in vivo screening platform to enable selective and efficient targeting of designated cells and tissues. Licensed to pharmaceutical partners for use in RNA and DNA-based therapeutics and vaccines.
  • In Vivo Mass Screening Platform A proprietary screening platform that uses molecular barcoding to simultaneously evaluate hundreds of lipid nanoparticle formulations in vivo with rapid feedback loops. Identifies and quantifies nanoparticle biodistribution at single-cell resolution and uses AI analysis to select optimal delivery vehicles for each target tissue or cell.
  • Lipid-Based Nanoparticle Delivery Vehicles Proprietary lipid-based nanoparticle formulations for delivery of RNA and DNA-based therapies to targets beyond the liver, optimized for selective indications including hard-to-treat cancers, metabolic diseases, and other therapeutic areas. Made available to pharmaceutical partners through co-development and licensing arrangements.

Quantifiable outcome

  • Hundreds of delivery vehicles developed and tested for different therapeutic drugs
  • +2 more outcomes

Companies that use Barcode

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Barcode technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature4 records

Barcode partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Galmed PharmaceuticalscoreStrategic or Co-development Partner · 9 April 2026Galmed Pharmaceuticals partnered with Barcode Nanotech to develop a brain-penetrating formulation of Aramchol (SCD1 inhibitor) using lipid nanoparticles for treating CNS diseases such as Parkinson's disease. The formulation is based on Barcode's proprietary nanoparticle platform and plans to advance to clinical trials in 2026.

Scale indicators4 records

Recent moves5 records

Expansion highlights5 records

Barcode competitors and assessment

Company assessment

Others

  • Cytiva (formerly Precision NanoSystems): Cytiva acquired Precision NanoSystems, a provider of LNP formulation instruments and lipid libraries used by RNA therapy developers. It is an enabling technology supplier and adjacent competitor whose lipid library offerings overlap with portions of Barcode's proprietary lipid asset.

Emerging players

  • Sirnaomics: Sirnaomics is a clinical-stage RNA therapeutics company with its own siRNA and mRNA delivery platforms targeting tumors and fibrotic diseases. It is an emerging peer with partial overlap in delivery-driven RNA approaches for oncology and metabolic indications that Barcode also pursues.
  • CureVac: CureVac is an mRNA technology company developing its own lipid delivery formulations for vaccines and therapeutics. It is an emerging player that competes with Barcode for partnerships where RNA delivery know-how is a key differentiator, and overlaps on the RNA vaccine delivery use case.
  • Eveon: Eveon develops microfluidic formulation and manufacturing platforms for lipid nanoparticles and complex injectable drugs. It is an emerging peer addressing the same LNP formulation and process development market that Barcode's platform touches through its proprietary lipid library and screening workflow.

Broad incumbents

  • Alnylam Pharmaceuticals: Alnylam is the established leader in RNA-targeted therapeutics (siRNA) with proprietary conjugate-based delivery (GalNAc) and growing LNP programs. It is a broad incumbent addressing many of the same therapeutic indications Barcode targets, and represents the type of large pharma partner Barcode's LNP platform is designed to serve.
  • BioNTech: BioNTech is a vertically integrated mRNA therapeutics company with internal LNP capabilities and the resources to develop next-generation delivery formulations. It is a broad incumbent that competes with Barcode both as a potential partner and a potential internal-development alternative for pharma partners evaluating LNP technologies.
  • Moderna: Moderna operates one of the largest internal LNP and mRNA delivery programs globally, with extensive in-house lipid libraries and biodistribution know-how. It is a broad incumbent whose size and resources set the benchmark Barcode's differentiated screening platform must beat on cost, speed, or tissue selectivity.

Direct peers

  • Acuitas Therapeutics: Acuitas is the leading independent LNP delivery technology company, supplying ionizable lipids used in Comirnaty and other approved RNA therapeutics. It is the most directly comparable peer to Barcode, competing head-to-head for pharma LNP licensing deals targeting tissues beyond the liver.
  • Genevant Sciences: Genevant develops lipid nanoparticle and other delivery technologies for RNA therapeutics, licensing its platform to multiple pharma partners. It competes directly with Barcode for enterprise partnerships and embodies the same platform-licensing business model.
  • Arcturus Therapeutics: Arcturus combines proprietary LNP delivery technology with its own RNA therapeutic pipeline, including rare disease and infectious disease programs. It is a direct peer in the targeted RNA delivery space and operates a hybrid licensing-plus-product model similar to where Barcode could evolve.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Barcode social profiles

Digital presence

Barcode financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Barcode leadership team

Management profile

Number of profiles

Profiles6 records

Barcode funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Barcode M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Barcode

What does Barcode do?

Barcode Nanotech develops and licenses proprietary lipid nanoparticle (LNP) delivery vehicles and an AI-powered in vivo screening platform that enables pharmaceutical partners to deliver RNA and DNA-based therapeutics and vaccines to precise tissue and cellular targets beyond the liver. The company partners with pharma and vaccine developers on co-development, licensing, and R&D collaboration arrangements.

Is Barcode a public or private company?

Barcode is a private company. It is classified as venture growth investor backed and is currently operating.

When was Barcode founded?

Barcode was founded in 2017. It employs 1 to 10 people.

Where is Barcode based?

Barcode is headquartered in Nazareth, Israel, in the Middle East region.

How does Barcode make money?

Two revenue lines are on record. Partnership and Licensing Deals are the primary driver. The others are research and Development Collaborations.

Who are Barcode's main competitors?

Cytiva (formerly Precision NanoSystems) is listed as an others. Emerging players are Sirnaomics, CureVac and Eveon. Broad incumbents are Alnylam Pharmaceuticals, BioNTech and Moderna. Direct peers are Acuitas Therapeutics, Genevant Sciences and Arcturus Therapeutics.

Does Barcode have an API?

No public API is recorded for Barcode.

What industry is Barcode in?

Barcode's product category is Drug Delivery Technology. Its primary akta.pro industry code is HLAAADAD, RNA Delivery Technologies (LNPs, polymers, conjugates incl. GalNAc, peptides, exosomes), with a secondary code of HLAAACAC, Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Stock TitanEocene develops Aramchol LNP formulation for tumor targetingEocene and Barcode Nanotech developed a novel Aramchol lipid nanoparticle formulation using FDA-approved lipids to target the tumor microenvironment in liver and GI tumors. The formulation aims to selectively inhibit fibrosis-driving cells, potentially enhancing immunotherapy and standard-of-care treatments for these cancers.PR NewswireEocene and Barcode Nanotech Report Progress in the Development of Tumor Microenvironment-Targeted Lipid Nanoparticles Formulation of AramcholEocene's subsidiary Galmed, with Barcode Nanotech, developed a novel Aramchol lipid nanoparticle formulation targeting the tumor microenvironment in liver and GI tumors. The formulation aims to selectively inhibit fibrosis-driving cells, potentially enhancing immunotherapy and standard-of-care treatments. The company expects to accelerate the antifibrotic effect observed with oral Aramchol.t.co / TwitterGalmed Accelerates Heart Failure Innovation with AramcholGalmed Pharmaceuticals announced a breakthrough lipid nanoparticle (LNP) formulation of its investigational drug Aramchol, developed in collaboration with Barcode Nanotech, that redirects biodistribution from the liver to heart tissue to potentially treat cardiac fibrosis. Traditional Aramchol formulations accumulate 80–90% in the liver, but the new cardiac-targeted approach uses AI-enabled nanoparticle engineering and FDA-approved lipids to selectively deliver the drug to heart muscle. This advancement positions Aramchol as a potential first-in-class therapy for cardiac fibrosis, which contributed to approximately 20.5 million deaths globally in 2025, with no currently approved therapies directly targeting the fibrotic remodeling process.AdvfnGalmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, AramcholGalmed Pharmaceuticals announced the breakthrough development of a novel lipid nanoparticle (LNP) formulation of its SCD1 inhibitor Aramchol that selectively targets heart tissue, developed in collaboration with Barcode Nanotech. The new formulation addresses a major limitation of traditional Aramchol, which accumulates 80-90% in the liver with limited cardiac effect, and aims to treat cardiac fibrosis responsible for approximately 20.5 million deaths globally in 2025. The companies plan to develop modified LNPs targeting specific cardiac cell types as a potential disease-modifying therapy for cardiovascular disease.PR NewswireGalmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, AramcholGalmed Pharmaceuticals announced the breakthrough development of a brain-penetrating formulation of its SCD1 inhibitor Aramchol, co-developed with Barcode Nanotech using lipid nanoparticle technology to cross the blood-brain barrier. In-vitro studies demonstrated that Aramchol effectively down-regulated αSyn-aggregation in a dose-dependent manner, positioning it as a potential disease-modifying therapy for Parkinson disease and other synucleinopathies that currently have no treatment options. The companies plan to advance to Proof of Concept Phase 1b/2 studies in Parkinson disease patients in H2 2026.HackerNoonC# Barcode Library In-Depth Comparison: Ranked by Use CaseThe IronBarcode team published a detailed comparison of 12 C# barcode libraries, evaluating them across symbology support, read/write capability, API ergonomics, cross-platform compatibility, .NET 8+ support, and total cost of ownership. The libraries reviewed span from open-source options like ZXing.Net (~7M NuGet downloads) and QRCoder (~15M downloads) to commercial offerings ranging from $749 to $1,469+ per developer. IronBarcode positions itself as offering the strongest balance of API simplicity, format coverage (50+ symbologies), cross-platform deployment, and price among commercial options, while acknowledging where competitors excel in specific areas such as Dynamsoft's camera-feed recognition accuracy or LEADTOOLS' symbology breadth (100+).MarketplaceBritish textiles get an unexpected boost from COVID-19British clothing retailers are shifting orders back to domestic textile manufacturers as COVID-19 disruptions in China expose the risks of long international supply chains. Paul James Knitwear in Leicester expects production to increase by 20–30%, with other local manufacturers like Barcode Design also reporting a surge in inquiries from retailers seeking to spread risk. Industry analysts believe the coronavirus pandemic will permanently alter the clothing industry's approach to sourcing, benefiting British manufacturers.